Skip to main content
TheraVet SA logo

TheraVet SA — Investor Relations & Filings

Ticker · ALVET ISIN · BE0974387194 LEI · 984500804EBR3F1EFF71 BR Manufacturing
Open in API
Filings indexed 239 across all filing types
Latest filing 2022-04-06 Earnings Release
Country BE Belgium
Listing BR ALVET

About TheraVet SA

https://www.egeiro.com/

TheraVet SA is a veterinary biotechnology company specializing in the development and commercialization of treatments for osteoarticular diseases in companion animals. The company focuses on creating a portfolio of pharmaceutical products and solutions designed to manage bone and joint conditions, such as osteoarthritis. Its primary objective is to provide innovative therapeutic options to improve the mobility and quality of life for pets.

Recent filings

Filing Released Lang Actions
Inside Information / Information on annual revenues
Earnings Release Classification · 100% confidence The document is titled "TheraVet reports Full Year 2021 Financial Results and confirms its ambitious development and commercial plans for 2022." It contains a detailed table of 'Full year 2021 financial results' including Revenue, EBITDA, and Net Profit/loss, along with extensive operational highlights and management commentary covering the entire fiscal year ending December 31, 2021. This structure is characteristic of an Earnings Release (ER) or a Management Discussion & Analysis (MDA) section often included within a larger annual filing. However, the document explicitly states: "The 2021 annual report ending December 31, 2021 will be published April 07, 2022..." This indicates the current document is the preliminary announcement of the annual results, not the final, comprehensive 10-K filing itself. Since it provides the full annual financial highlights and management discussion immediately following the close of the fiscal year, it fits the definition of an Earnings Release (ER) best, as it is the initial announcement of the period's results. FY 2021
2022-04-06 English
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 100% confidence The document is titled "TheraVet publie ses résultats annuels de l'exercice 2021..." and explicitly states: "TheraVet présente aujourd'hui ses résultats annuels pour l'exercice clos le 31 décembre 2021, fait le point sur ses activités et confirme ses perspectives de développement et commerciales pour 2022." It contains a detailed table of 'Résultats financiers annuels de l'exercice 2021' (Annual financial results for the 2021 fiscal year) and discusses operational highlights for the year. This content strongly indicates a comprehensive annual financial disclosure. Although it mentions the formal 'Rapport annuel 2021' will be published the next day (April 7, 2022), the current document serves as the primary release of the annual results, which aligns best with the definition of an Earnings Release (ER) or, given the depth of financial tables and operational review, potentially an Annual Report (10-K) substitute if it were a US filer. However, since it is a detailed summary of the full year's performance released by a non-US company, and it contains the core financial data, it is most accurately classified as an Earnings Release (ER) summarizing the annual performance, or potentially an Interim/Quarterly Report (IR) if the company typically uses this format for annual summaries, but 'ER' is the closest fit for a primary results announcement. Given the comprehensive nature covering the *entire* fiscal year and including detailed financial tables, it is more substantial than a typical quarterly ER. Since the document explicitly covers the full year results and contains audited figures (mentioning PWC), it functions as the primary annual financial disclosure, making it analogous to a 10-K, but since 10-K is reserved for SEC filings, and this is a comprehensive annual summary, 'ER' (Earnings Release) is the most appropriate category for a primary results announcement, even if it's annual in scope, unless a specific 'Annual Report' code existed for non-10-K filings. Given the options, 'ER' captures the essence of announcing the period's results. If the document were the actual, full statutory annual report, 10-K would be used for US filers, but for non-US comprehensive annual results, ER is the standard classification for the initial release of these figures. FY 2021
2022-04-06 French
Market-making agreement with Banque Rothschild
Regulatory Filings Classification · 95% confidence The document is a press release announcing a market-making agreement between TheraVet and Banque Rothschild Martin Maurel to provide liquidity for its shares. This type of corporate announcement regarding market-making activities and liquidity provision does not fit into specific categories like M&A, dividends, or director dealings, and is best classified as a general regulatory announcement or corporate update.
2022-03-28 English
Mise en œuvre d’un contrat d’animation de marché avec la banque Rothschild
Capital/Financing Update Classification · 95% confidence The document is a press release announcing the implementation of a market-making contract (contrat d'animation de marché) between TheraVet and Banque Rothschild. This type of announcement relates to capital market activities and liquidity management, which does not fit into specific categories like earnings, dividends, or board changes. As it is a general regulatory announcement regarding company operations and market presence, it falls under the 'Regulatory Filings' (RNS) category.
2022-03-28 French
Implementatie van marktmakersovereenkomst met bank Rothschild
Capital/Financing Update Classification · 99% confidence The document is a press release dated March 28, 2022, announcing the implementation of a market maker agreement with Banque Rothschild to improve stock liquidity. It also mentions an upcoming announcement of '2021 Jaarresultaten' (2021 Annual Results) on April 6, 2022. The core subject is a corporate action related to market operations and financing/liquidity management, specifically involving an agreement with a bank to support the stock price. This fits best under 'Capital/Financing Update' (CAP) as it directly relates to maintaining the structure and liquidity of the company's traded capital, or potentially 'Regulatory Filings' (RNS) if it were a general announcement. Given the specific nature of establishing a market maker agreement to manage capital structure/trading, CAP is the most precise fit among the options, as it deals with financing mechanisms and capital market support, distinct from insider trading (DIRS) or dividend announcements (DIV). It is not an ER, IR, 10-K, or AR, as it is not a financial results report itself.
2022-03-28 Dutch
Inside Information / Other news releases
Report Publication Announcement Classification · 99% confidence The document is a press release dated March 28, 2022, announcing a market-making agreement between TheraVet and Banque Rothschild Martin Maurel. It details the purpose of the agreement (providing liquidity) and mentions related share lending and waiver of lock-up requirements. It also includes a forward-looking statement about the 'Next press release: 2021 Full-year annual results April 6, 2022 before market opening'. Since the document is a specific announcement about a corporate action (market-making agreement) that does not fit into the primary categories like 10-K, ER, or DIV, and it is not a general regulatory filing fallback (RNS) or a report announcement (RPA), it most closely aligns with a general corporate update or financing/capital structure activity. However, market-making agreements are often related to ensuring smooth trading, which is a general corporate announcement. Given the options, this type of specific, non-financial result announcement that isn't about management change (MANG) or insider trading (DIRS) is best categorized as a general Regulatory Filing (RNS) as it is a formal announcement to the market that doesn't fit the more specific codes. It is too detailed for a simple RPA and is not a core financial report or capital change announcement.
2022-03-28 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.